Denali Therapeutics, Inc. (DNLI)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$18.41-1.34%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Denali Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
Revenue (AVLAYAH)	$10M–$12M	—
FY 2026 · Q4
Revenue	—	22.8M
EPS	—	-0.631
FY 2026 · Annual
Revenue	—	38.91M
EPS	—	-2.246
FY 2027 · Annual
Revenue	—	130.62M
EPS	—	-2.364

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage financial obligations including new direct obligations	It is managing financial obligations and adjusting to partnership changes.	Improving	Financial obligations increase materially or liquidity stress worsens in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Adjust to termination of Takeda collaboration	It is managing financial obligations and adjusting to partnership changes.	Intact	Material delays or losses arise from partnership termination in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Deliver first TV-enabled medicine by end of 2026	Denali aims to deliver its first TV-enabled medicine by the end of 2026.	Improving	Failure to deliver the first TV-enabled medicine by end of 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.36

$-2.44 → $-2.36 · observed estimates

FY2027 revenue$0.13B

$0.11B → $0.13B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.44	$106,366,871	15 / 16
2026-07-25	$-2.44	$106,366,871	15 / 16
2026-07-26	$-2.44	$106,366,871	15 / 16
2026-07-27	$-2.53	$103,653,570	16 / 20
2026-07-28	$-2.53	$103,653,570	16 / 20
2026-07-29	$-2.44	$106,366,871	15 / 16
2026-07-30	$-2.53	$103,653,570	16 / 20
2026-07-31	$-2.44	$106,366,871	15 / 16
2026-08-01	$-2.44	$106,366,871	15 / 16
2026-08-02	$-2.53	$103,653,570	16 / 20
2026-08-03	$-2.53	$103,653,570	16 / 20
2026-08-04	$-2.53	$103,653,570	16 / 20
2026-08-05	$-2.53	$103,653,570	16 / 20
2026-08-06	$-2.44	$106,366,871	15 / 16
2026-08-07	$-2.44	$106,366,871	15 / 16
2026-08-08	$-2.52	$105,595,040	16 / 18
2026-08-09	$-2.52	$105,595,040	16 / 18
2026-08-10	$-2.52	$105,595,040	16 / 18
2026-08-11	$-2.44	$106,366,871	15 / 16
2026-08-12	$-2.43	$129,179,630	17 / 19
2026-08-13	$-2.43	$129,179,630	17 / 19
2026-08-14	$-2.44	$106,366,871	15 / 16
2026-08-15	$-2.44	$106,366,871	15 / 16
2026-08-16	$-2.44	$106,366,871	15 / 16
2026-08-17	$-2.44	$106,366,871	15 / 16
2026-08-18	$-2.44	$106,366,871	15 / 16
2026-08-19	$-2.44	$106,366,871	15 / 16
2026-08-20	$-2.34	$132,271,920	16 / 15
2026-08-21	$-2.34	$132,271,920	16 / 15
2026-08-22	$-2.34	$132,271,920	16 / 15
2026-08-23	$-2.34	$132,271,920	16 / 15
2026-08-24	$-2.34	$132,271,920	16 / 15
2026-08-25	$-2.34	$132,271,920	16 / 15
2026-08-26	$-2.34	$129,883,030	16 / 15
2026-08-27	$-2.34	$129,883,030	16 / 15
2026-08-28	$-2.34	$129,883,030	16 / 15
2026-08-29	$-2.34	$129,883,030	16 / 15
2026-08-30	$-2.34	$129,883,030	16 / 15
2026-08-31	$-2.34	$129,883,030	16 / 15
2026-09-01	$-2.34	$129,883,030	16 / 15
2026-09-02	$-2.34	$129,883,030	16 / 15
2026-09-03	$-2.34	$129,883,030	16 / 15
2026-09-04	$-2.34	$129,883,030	16 / 15
2026-09-05	$-2.34	$129,883,030	16 / 15
2026-09-06	$-2.34	$129,883,030	16 / 15
2026-09-07	$-2.34	$129,883,030	16 / 15
2026-09-08	$-2.34	$129,883,030	16 / 15
2026-09-09	$-2.34	$129,883,030	16 / 15
2026-09-10	$-2.35	$129,520,766	16 / 15
2026-09-11	$-2.35	$129,520,766	16 / 15
2026-09-12	$-2.35	$129,520,766	16 / 15
2026-09-13	$-2.35	$129,520,766	16 / 15
2026-09-14	$-2.35	$129,520,766	16 / 15
2026-09-15	$-2.35	$129,520,766	16 / 15
2026-09-16	$-2.35	$129,520,766	16 / 15
2026-09-17	$-2.35	$129,520,766	16 / 15
2026-09-18	$-2.35	$129,520,766	16 / 15
2026-09-19	$-2.35	$129,520,766	16 / 15
2026-09-20	$-2.35	$129,520,766	16 / 15
2026-09-21	$-2.35	$129,520,766	16 / 15
2026-09-22	$-2.35	$129,520,766	16 / 15
2026-09-23	$-2.35	$129,520,766	16 / 15
2026-09-24	$-2.35	$129,520,766	16 / 15
2026-09-25	$-2.35	$130,362,872	16 / 15
2026-09-26	$-2.35	$130,362,872	16 / 15
2026-09-27	$-2.35	$130,362,872	16 / 15
2026-09-28	$-2.35	$130,362,872	16 / 15
2026-09-29	$-2.35	$130,362,872	16 / 15
2026-09-30	$-2.35	$130,362,872	16 / 15
2026-10-01	$-2.35	$130,362,872	16 / 15
2026-10-02	$-2.35	$130,362,872	16 / 15
2026-10-03	$-2.35	$130,362,872	16 / 15
2026-10-04	$-2.35	$130,362,872	16 / 15
2026-10-05	$-2.35	$130,362,872	16 / 15
2026-10-06	$-2.35	$130,362,872	16 / 15
2026-10-07	$-2.35	$130,362,872	16 / 15
2026-10-08	$-2.35	$130,362,872	16 / 15
2026-10-09	$-2.35	$130,362,872	16 / 15
2026-10-10	$-2.35	$130,362,872	16 / 15
2026-10-11	$-2.35	$130,362,872	16 / 15
2026-10-12	$-2.35	$130,362,872	16 / 15
2026-10-13	$-2.35	$130,362,872	16 / 15
2026-10-14	$-2.35	$130,362,856	16 / 15
2026-10-15	$-2.35	$130,362,856	16 / 15
2026-10-16	$-2.34	$130,789,488	16 / 15
2026-10-17	$-2.34	$130,789,488	16 / 15
2026-10-18	$-2.34	$130,789,488	16 / 15
2026-10-19	$-2.34	$130,789,488	16 / 15
2026-10-20	$-2.34	$130,789,488	16 / 15
2026-10-21	$-2.36	$130,616,909	16 / 15
2026-10-22	$-2.36	$130,616,909	16 / 15
2026-10-23	$-2.36	$130,616,909	16 / 15
2026-10-24	$-2.36	$130,616,909	16 / 15

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	18	1
2026-06-01	18	1
2026-07-01	19	1
2026-08-01	19	1
2026-09-01	19	1
2026-10-01	19	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 19 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage financial obligations including new direct obligationsDirect metric needs a verified mapping
Adjust to termination of Takeda collaborationDirect metric needs a verified mapping
Deliver first TV-enabled medicine by end of 2026Direct metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.7%Typical daily move · historical

Downside history

-35.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Denali Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative growth, with elevated risk and no current earnings base. The multi-year view is on watch: commercial execution is advancing, but results have lagged the industry cohort and key clinical evidence is still ahead.

What's priced into Denali Therapeutics, Inc.

DNLI trades at a durable premium to peers, with medium confidence in that valuation assessment. The evidence does not specify the market’s exact expectations, but the premium suggests investors already credit some durability to the business despite ongoing losses; there is little sign of near-term pricing fragility.

What the fundamentals likely do

Near term, AVLAYAH provides an early commercial growth signal: it generated product revenue in Q2, and management projects higher Q3 revenue, alongside expanding payer coverage and commercial infrastructure. The trajectory is mixed because DNL593 results moved from a planned 2026 report to 2027, while the platform pipeline advanced and recent financial performance remains below its industry cohort.

What Denali Therapeutics, Inc. hinges on

The multi-year thesis hinges on AVLAYAH sustaining commercial growth and on clinical programs producing useful evidence, including the delayed DNL593 results. A guidance cut or further weakening in jobs data would add risk, while stronger results and guidance from sector bellwethers could support the broader healthcare backdrop.